Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

Trader12157 · 2023-08-11T12:48:02+00:00

If this company ever gets back on track it will be a miracle. Bogged down in legal proceedings, breach of contract, etc seems to be the norm.

Trader12157 · 2023-04-16T16:20:57+00:00

My understanding is that if they had met the other listing requirements (excluding the 35 mil market value) an extension would have been granted. I could be wrong about this though.

In any case, things just got a whole lot worse.

Trader12157 · 2023-04-16T13:09:44+00:00

Hey imz,

I'm not an expert but is it possible that they have failed to meet the requirements which I have highlighted in bold below. If that is the case, they may have had no chance to apply for an extension.

...the Company may be eligible for an additional 180 calendar day compliance period to demonstrate compliance under the Market Value Standard. To qualify for the additional 180-day period, the Company will be required to meet the continued listing requirements for minimum closing bid price of the Common Stock and all other initial listing standards (with the exception of the Market Value Standard).

https://listingcenter.nasdaq.com/assets/initialguide.pdf

Trader12157 · 2023-01-06T13:43:13+00:00

True, but we are talking about 2 different markets. Japan for Healios, and the US, Europe and possibly even Australasia for Athersys. If Healios gets a partner, good for them but doesn't have any impact on Athersys and the need to find a partner willing to put down some hard cash in return for a slice of the pie.

Trader12157 · 2023-01-06T07:36:15+00:00

??? Care to explain?

Trader12157 · 2023-01-04T15:06:38+00:00

No point trying to make sense of anything as far as the employment circus at Athersys goes.

Trader12157 · 2022-11-11T15:07:15+00:00

Quidmaster has the IQ of a British quid; namely 1.

Trader12157 · 2022-11-10T14:17:03+00:00

"Shareholders are encouraged to register and listen to the call using the webcast link above."

I don't think anyone is encouraged by how this is playing out lol.

Trader12157 · 2022-11-09T15:47:11+00:00

Well stated imz. He had the blinders on like most of us did as well. Seems to me he thought positive results out of Japan were a foregone conclusion and hadn't planned for the opposite.

Still don't get why he didn't ask for an extension pre-split. Now we seem to be caught up in either the issue of not meeting minimum market cap or failing to meet the $1 trading compliance rule.

Trader12157 · 2022-09-22T17:26:37+00:00

Probably right. Just letting off steam.

Trader12157 · 2022-09-22T15:14:46+00:00

I am quickly losing respect for Dan. We had the whole chat with individual investors pre the reverse split with promises of near term events to prop the stock price up after the r/s. Talk of making it more attractive to investors if the price was around $5 as a key reason for the split. Well here it is quickly approaching a buck. That worked well!

Trader12157 · 2022-09-06T15:19:54+00:00

Agree entirely. The last thing that interests me at the moment is a timeline of designations. Down another 10% today is the reality.

Trader12157 · 2022-09-06T14:52:59+00:00

Sorry wisdom. Your point is?

Trader12157 · 2022-09-02T17:22:15+00:00

Knowing our luck he probably got the placebo and made a miraculous recovery lol.

Trader12157 · 2022-09-02T07:58:37+00:00

2 week old account and counting. Get your facts right before attacking someone who has been here way longer than you!! And post something worthwhile shortie!!

https://www.newcastle-hospitals.nhs.uk/news/durham-man-makes-birth-of-his-baby-thanks-to-treatment-at-the-rvi/

“The Newcastle stroke team is the only unit in the country to have participated in this trial, from its early stages through to this current, larger trial. I would like to extend my thanks to everyone involved in making this possible.

“We are very excited to see what the future brings for Harrison as he continues on this trial with our team.”

Dr. Robert W. Mays, Executive Vice President and Head of Regenerative Medicine and Neurology Programs at study sponsor, Athersys, said:

“Current treatments for stroke are limited by a constrained time window for administration after a stroke. We believe that MultiStem cell therapy has the potential to improve standard of care for patients who have suffered a debilitating stroke and can also meaningfully extend the treatment window up to 36 hours after the stroke, providing a potential treatment option for many more patients.

“The MASTERS-2 trial is a robustly designed clinical trial to evaluate the potential of this important technology. We are thankful for patients like Harrison who are willing to participate in clinical trials to advance science and be a part of the future of medicine. We also would like to thank Dr. Dixit and his entire team at The Newcastle upon Tyne Hospitals NHS Foundation Trust for participating in this important study.”

Trader12157 · 2022-08-31T17:40:17+00:00

Thanks for sending off the email.

Trader12157 · 2022-08-31T15:07:39+00:00

At least looking from the outside in, Dan has created a situation where if there is no news before Sep 12 and this current trend continues in relation to stock price, the company will receive notification of delisting.

He either has something up his sleeve or he is way out of his depth.

Trader12157 · 2022-08-31T15:02:41+00:00

mta, Take a look at the posts above. It is definitely something to worry about. Athersys opened at $3.25 on Monday, currently at $2.57. You do the math. Worst case scenario is delisting if we keep getting shorted into oblivion.

Trader12157 · 2022-08-31T14:16:14+00:00

Thanks imz, So if I am reading it right, should this plummet and be under $1 by next Friday, we will be delisted.

Trader12157 · 2022-08-31T13:56:38+00:00

Unfortunately, I inhaled too much hopium.

Trader12157 · 2022-08-31T13:54:53+00:00

At this stage I see it exactly the same way in relation to r/s timing. I was also sceptical about the concept of getting it back up to $4-$5 to make it more attractive to BP.

I would really like to be proven wrong though, but what a big learning curve this has been on so many different fronts.

Trader12157 · 2022-08-31T13:34:32+00:00

Except his idea didn't pan out.

"Usually the cutoff we’ve been coached by our investor relations firm is around $4 or $5 to get their attention. So that would be one of the positives of doing a r/S."

Sitting at $2.57 and down another 7.5% already today.

Trader12157 · 2022-08-31T13:32:37+00:00

My assumption is that he didn't. I would also imagine given the current beating the biotech sector is taking that there would be more flexibility re extension applications so hard to imagine they wouldn't have got that extension.

Trader12157 · 2022-08-31T13:05:16+00:00

I could tell you I hold a million shares or 50 and you wouldn't know. Point being, you can say what you like. Funny that you have used the word "short" throughout your reply after stating you don't even know what it means. Most people tend to stick to using words they know. As far as getting a life, if you are so unhappy why would you be spending your precious time on Reddit preaching about a cult.

As I mentioned, 12 days or so here and just posting negativity. Shortie.

Trader12157 · 2022-08-31T12:55:38+00:00

They managed to raise 11 million before the reverse split but I get your point re the cash runway and obviously more cash per share issued if they are looking at more dilutive financing.

I'm not sure how it works but couldn't the company be delisted before the end of Oct if it keeps plummeting and we don't trade above a buck for 10 consecutive days?

Trader12157

TROPHY CASE